Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics
Clinical Pharmacology & Therapeutics · 2023-03 · 113 (3) · 585-599
DOI: 10.1002/cpt.2714 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.08.2022. Verfasst von Lorenzo E Thompson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Stroke, Atrial Fibrillation. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NHGRI NIH HHS.
Abstract (Originalsprache)
Oral anticoagulants (OACs) are commonly used to reduce the risk of venous thromboembolism and the risk of stroke in patients with atrial fibrillation. Endorsed by the American Heart Association, American College of Cardiology, and the European Society of Cardiology, direct oral anticoagulants (DOACs) have displaced warfarin as the OAC of choice for both conditions, due to improved safety profiles, fewer drug–drug and drug–diet interactions, and lack of monitoring requirements. Despite their widespread use and improved safety over warfarin, DOAC‐related bleeding remains a major concern for patients. DOACs have stable pharmacokinetics and pharmacodynamics; however, variability in DOAC response is common and may be attributed to numerous factors, including patient‐specific factors, concomitant medications, comorbid conditions, and genetics. Although DOAC randomized controlled trials included patients of varying ages and levels of kidney function, they failed to include patients of diverse ancestries. Additionally, current evidence to support DOAC pharmacogenetic associations have primarily been derived from European and Asian individuals. Given differences in genotype frequencies and disease burden among patients of different biogeographic groups, future research must engage diverse populations to assess and quantify the impact of predictors on DOAC response. Current under‐representation of patients from diverse racial groups does not allow for proper generalization of the influence of clinical and genetic factors in relation to DOAC variability. Herein, we discuss factors affecting DOAC response, such as age, sex, weight, kidney function, drug interactions, and pharmacogenetics, while offering a new perspective on the need for further research including frequently excluded groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Brittney H Davis
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NHGRI NIH HHS
- National Institutes of Health
Zitieren
APA
Thompson, L. E., Davis, B. H., Narayan, R., Goff, B., Brown, T. M., & Limdi, N. A. (2023). Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics. Clinical Pharmacology & Therapeutics, 113(3), 585-599. https://doi.org/10.1002/cpt.2714
Vancouver
Thompson LE, Davis BH, Narayan R, Goff B, Brown TM, Limdi NA. Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics. Clinical Pharmacology & Therapeutics. 2023;113(3):585-599. doi:10.1002/cpt.2714
BibTeX
@article{Thompson2023,
author = {Thompson, Lorenzo E and Davis, Brittney H and Narayan, Renuka and Goff, Blake and Brown, Todd M and Limdi, Nita A},
title = {Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {113},
number = {3},
pages = {585--599},
doi = {10.1002/cpt.2714}
}
EUVIMED